| Followers | 0 |
| Posts | 1357 |
| Boards Moderated | 0 |
| Alias Born | 03/20/2022 |
Tuesday, December 31, 2024 5:45:34 PM
The intent of the India Trial is to gather preliminary safety and efficacy data that could be pertinent to Vivo's pending IDE submission to the FDA, NOT to ""cure"" those patients.
That was made evidently clear by the type of patients that were selected, ie, those with few or no other treatment options available for their persistent ailment.
The fact that you keep accusing others of lying all the while blatantly lying yourself simply proves how much of an utter fraud, with an obvious agenda, you are!
ema_lurker DD @ Stock twits...........
1. Trial Overview and Design
Phase 1/2 Study: The trial is focused on testing the safety and initial efficacy of RadioGel™ for treating solid metastatic tumors in lymph nodes.
2. Target Patient Population
Inclusion Criteria:
Patients with recurrent or metastatic solid tumors in lymph nodes, who are poor candidates for surgery or external beam radiation.
#SCEEATE
That was made evidently clear by the type of patients that were selected, ie, those with few or no other treatment options available for their persistent ailment.
The fact that you keep accusing others of lying all the while blatantly lying yourself simply proves how much of an utter fraud, with an obvious agenda, you are!
ema_lurker DD @ Stock twits...........
1. Trial Overview and Design
Phase 1/2 Study: The trial is focused on testing the safety and initial efficacy of RadioGel™ for treating solid metastatic tumors in lymph nodes.
2. Target Patient Population
Inclusion Criteria:
Patients with recurrent or metastatic solid tumors in lymph nodes, who are poor candidates for surgery or external beam radiation.
#SCEEATE
Recent RDGL News
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2025 09:14:29 PM
